Kodiak Sciences Inc (KOD) News
Filter KOD News Items
KOD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KOD News Highlights
- KOD's 30 day story count now stands at 2.
- Over the past 23 days, the trend for KOD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest KOD News From Around the Web
Below are the latest news stories about KODIAK SCIENCES INC that investors may wish to consider to help them evaluate KOD as an investment opportunity.
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023, at 3:25 p.m. Eastern Time (12:25 p.m. Pacific Time). |
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline UpdatesKodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans. |
Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ...Key Financial Highlights and Pipeline Developments |
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business HighlightsKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the trading week right with a breakdown of the biggest pre-market stock movers worth noting on Monday morning! |
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submissionKodiak Sciences Inc. (NASDAQ: KOD) today announced that its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to severe NPDR met its one-year primary endpoint. |
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETINGKodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 3-6 in San Francisco. |
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina SocietyKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON |